Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology and Risk Factors
06.2.1 Modifiable Risk Factors
06.2.2 Non-modifiable Risk Factors
06.3 Pathophysiology
06.4 Signs and Symptoms
06.5 Diagnosis
06.5.1 ECG
06.5.2 Stress Testing
06.5.3 Echocardiography
06.5.4 Chest X-Ray
06.5.5 Blood Tests
06.5.6 Coronary Angiography and Cardiac Catheterization
06.6 Management
06.6.1 Lifestyle Changes
06.6.2 Pharmacotherapy
06.6.3 Medical Procedures
06.7 Epidemiology
06.8 Economic Burden
07. Pipeline Analysis
07.1 Information on the Pipeline Candidates
07.1.1 ONO-1101
07.1.2 Ranolazine
07.1.3 Autologous CD34+ stem cells
07.1.4 Generx
07.1.5 Cryocell
07.1.6 RVX-208
07.1.7 MPSK3169A
07.1.8 GS-6615
07.1.9 JVS-100
07.1.10 LA-419
07.1.11 ALD-201
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Disease Class
09.1 Angina Pectoris
09.1.1 Stable Angina
09.1.2 Unstable Angina
09.1.3 Prinzmetal's Angina
09.2 MI
09.2.1 STEMI
09.2.2 NSTEMI
10. Market Segmentation by Drug Class
10.1 Anti-dyslipidemic Drugs
10.2 Calcium Channel Blockers
10.3 Beta-blockers
10.4 ACE Inhibitors
10.5 ARBs
10.6 Vasodilators
10.7 Antithrombotic Agents
11. Geographical Segmentation
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 AstraZeneca
19.2.2 Bayer
19.2.3 Eli Lilly
19.2.4 Novartis
19.2.5 Pfizer
19.2.6 Sanofi
19.3 Other and Future Prominent Vendors
20. Global IHD Drugs Market: Key Takeaways
21. Key Vendor Analysis
21.1 AstraZeneca plc
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Business Segmentation by Revenue 2011-2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Developments
21.1.8 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Eli Lilly
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue
21.3.4 Sales by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 Novartis AG
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 Pfizer
21.5.1 Key facts
21.5.2 Business overview
21.5.3 Business segmentation by revenue 2014
21.5.4 Business segmentation by revenue 2013 and 2014
21.5.5 Geographical segmentation by revenue 2014
21.5.6 Business strategy
21.5.7 Key developments
21.5.8 SWOT analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis
22. Other Reports in this Series